Market Cap 8.52B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 13.62
Forward PE 9.87
Profit Margin 43.74%
Debt to Equity Ratio 3.00
Volume 1,342,700
Avg Vol 2,367,122
Day's Range N/A - N/A
Shares Out 117.60M
Stochastic %K 54%
Beta 0.94
Analysts Sell
Price Target $78.75

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Sean29md
Sean29md Jan. 14 at 4:08 PM
$HALO Where is the 2026 guidance update? For the last 2 years, Halozyme did not present at JPM Healthcare conference (the most popular biopharma conference) but did the investor conference call with annual guidance update. Does the lack of investor call mean that they are so close to signing an MDASE licensing deal with Merck that Helen is waiting to update 2026 EPS guidance until the deal is done?
0 · Reply
Digitalization2026
Digitalization2026 Jan. 13 at 5:04 PM
$AKAN I get the comparison, but saying “just look at $HALO” doesn’t fully explain what’s happening with $AKAN 👇 Yes, Halo Collective had its own issues 🧨 — dilution, narrative swings, and weak execution. But $AKAN today is not the same setup. Different assets, different mechanics, different risk profile. What’s changed for $AKAN 📡 • Legacy cannabis assets were sold to survive 🌱❌ • Company pivoted to telecom infrastructure via First Towers & Fiber in Mexico 🇲🇽 • Post-split float is tight, borrow is expensive, and short interest remains elevated 🩳🔥 • Price is being driven by order flow + positioning, not hype posts Why the HALO comparison falls short 🤔 • $HALO was narrative driven • $AKAN is now asset + structure driven • Low float + shorts + any real news = fast repricing ⚡ Price targets 🎯 (speculative) • Base reclaim: $3–5 • Momentum breakout: $8–12 🚀 • Execution + squeeze: $15–25+ 🔥 Bottom line ⚠️ This is a high-risk restructuring trade, not a long-term hold yet. NFA 💎
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 2:42 PM
$HALO RSI: 60.88, MACD: 1.5444 Vol: 3.12, MA20: 69.10, MA50: 68.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
IN0V8
IN0V8 Jan. 8 at 5:00 PM
$HALO Buy TD Cowen raises target price to $90 from $79
1 · Reply
Sean29md
Sean29md Jan. 8 at 1:11 PM
$HALO Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE https://www.stocktitan.net/news/HALO/halozyme-announces-global-collaboration-and-license-agreement-with-r8le7w00unnq.html
0 · Reply
Sean29md
Sean29md Jan. 8 at 12:41 PM
$HALO Halozyme Therapeutics Inc.: TD Cowen raises target price to $90 from $79
0 · Reply
kej32
kej32 Jan. 7 at 6:22 PM
$HALO Good positive momentum heading into earnings! Let’s keep it going!!!
0 · Reply
Itinerant
Itinerant Jan. 2 at 7:21 PM
$HALO The price action is in a narrowing wedge. I am not a big technical analyst. I am a mathematical fundamental analyst. My analysis indicates that this stock is worth a lot more. So, I believe that the technical wedge pattern will break out strongly to the upside. JMO
0 · Reply
TalkMarkets
TalkMarkets Jan. 1 at 3:00 PM
Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882
0 · Reply
AnchorArc
AnchorArc Dec. 27 at 12:17 PM
$HALO Market participants want evidence that strategy converts to numbers; customer retention trends will be critical to monitor — measurable traction would outweigh rhetoric. Upside exists, but credibility must lead the way.
1 · Reply
Latest News on HALO
Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 5 weeks ago

Jim Lang Elected to Halozyme's Board of Directors


The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 2 months ago

The Big 3: OKLO, HALO, V

OKLO V


Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 2 months ago

Halozyme Just Bought Its Next Decade Of Growth


Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 3 months ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript


Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 4 months ago

Identify Superstar Stocks Like Halozyme with Money Flows


Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 4 months ago

Halozyme to Participate at Upcoming Investor Conferences


Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 7 months ago

Halozyme Therapeutics Added to Russell 1000® Index


Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 8 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat


Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 9 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings


Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 10 months ago

Halozyme Joins the $1 Billion Club


Sean29md
Sean29md Jan. 14 at 4:08 PM
$HALO Where is the 2026 guidance update? For the last 2 years, Halozyme did not present at JPM Healthcare conference (the most popular biopharma conference) but did the investor conference call with annual guidance update. Does the lack of investor call mean that they are so close to signing an MDASE licensing deal with Merck that Helen is waiting to update 2026 EPS guidance until the deal is done?
0 · Reply
Digitalization2026
Digitalization2026 Jan. 13 at 5:04 PM
$AKAN I get the comparison, but saying “just look at $HALO” doesn’t fully explain what’s happening with $AKAN 👇 Yes, Halo Collective had its own issues 🧨 — dilution, narrative swings, and weak execution. But $AKAN today is not the same setup. Different assets, different mechanics, different risk profile. What’s changed for $AKAN 📡 • Legacy cannabis assets were sold to survive 🌱❌ • Company pivoted to telecom infrastructure via First Towers & Fiber in Mexico 🇲🇽 • Post-split float is tight, borrow is expensive, and short interest remains elevated 🩳🔥 • Price is being driven by order flow + positioning, not hype posts Why the HALO comparison falls short 🤔 • $HALO was narrative driven • $AKAN is now asset + structure driven • Low float + shorts + any real news = fast repricing ⚡ Price targets 🎯 (speculative) • Base reclaim: $3–5 • Momentum breakout: $8–12 🚀 • Execution + squeeze: $15–25+ 🔥 Bottom line ⚠️ This is a high-risk restructuring trade, not a long-term hold yet. NFA 💎
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 2:42 PM
$HALO RSI: 60.88, MACD: 1.5444 Vol: 3.12, MA20: 69.10, MA50: 68.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
IN0V8
IN0V8 Jan. 8 at 5:00 PM
$HALO Buy TD Cowen raises target price to $90 from $79
1 · Reply
Sean29md
Sean29md Jan. 8 at 1:11 PM
$HALO Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE https://www.stocktitan.net/news/HALO/halozyme-announces-global-collaboration-and-license-agreement-with-r8le7w00unnq.html
0 · Reply
Sean29md
Sean29md Jan. 8 at 12:41 PM
$HALO Halozyme Therapeutics Inc.: TD Cowen raises target price to $90 from $79
0 · Reply
kej32
kej32 Jan. 7 at 6:22 PM
$HALO Good positive momentum heading into earnings! Let’s keep it going!!!
0 · Reply
Itinerant
Itinerant Jan. 2 at 7:21 PM
$HALO The price action is in a narrowing wedge. I am not a big technical analyst. I am a mathematical fundamental analyst. My analysis indicates that this stock is worth a lot more. So, I believe that the technical wedge pattern will break out strongly to the upside. JMO
0 · Reply
TalkMarkets
TalkMarkets Jan. 1 at 3:00 PM
Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882
0 · Reply
AnchorArc
AnchorArc Dec. 27 at 12:17 PM
$HALO Market participants want evidence that strategy converts to numbers; customer retention trends will be critical to monitor — measurable traction would outweigh rhetoric. Upside exists, but credibility must lead the way.
1 · Reply
Sean29md
Sean29md Dec. 26 at 7:38 PM
$HALO Don't be surprised if we have a repeat of last year's first quarter (+40% gains from Jan to March): "January 8, 2025: Halozyme reiterated 2024 guidance and raised its 2025 financial projections (Total Revenue: $1.15B-$1.225B; Adj. EBITDA: $755M-$805M; Non-GAAP EPS: $4.95-$5.35) and announced a $250M accelerated share repurchase"
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 2:18 PM
$HALO RSI: 74.38, MACD: -0.1669 Vol: 3.16, MA20: 65.61, MA50: 67.14 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VelocityOfM
VelocityOfM Dec. 25 at 10:41 AM
$HALO Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Progress needs to be observable in both leading indicators and reported metrics. Any disconnect between guidance and results will be magnified by sentiment. From here, delivery cadence—not ambition—will define investability.
0 · Reply
Sean29md
Sean29md Dec. 24 at 10:47 PM
$HALO Looks like Halozyme made another Enhanze deal but did not bother to publicize since it's with a tiny biotech, Sky Bioscience. https://d1io3yog0oux5.cloudfront.net/skyebioscience/sec/0001628280-25-058729/0001628280-25-058729.pdf
0 · Reply
Pittsburgh21
Pittsburgh21 Dec. 22 at 7:34 PM
0 · Reply
harmongreg
harmongreg Dec. 22 at 5:30 PM
Some Christmas shopping: $V Jan 355 calls, $HALO Jan 70 calls and $YETI Jan 47.50 calls
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:13 PM
$HALO Chart
0 · Reply
ortega1963
ortega1963 Dec. 22 at 3:16 PM
$HALO long 69.
0 · Reply
Trading0Analysis
Trading0Analysis Dec. 21 at 8:14 PM
$HALO daily: Primary uptrend from ~47 remains intact, but price is consolidating inside a descending channel after the 79.5 peak. Pullback has been controlled, holding above rising long-term MA (~63–65). Momentum is compressed, not broken. Key support is 64–65; as long as this holds, bias favors continuation. A break above 70–72 reclaims trend strength and opens a retest of 79.5. Loss of 63 increases downside risk toward 60.
0 · Reply
JFDI
JFDI Dec. 19 at 9:23 PM
$HALO is back @Doozio you glowin bruh
1 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 12:07 PM
HC Wainwright & Co. has updated their rating for Halozyme Therapeutics ( $HALO ) to Buy with a price target of 90.
0 · Reply
Sean29md
Sean29md Dec. 18 at 2:31 PM
$HALO Halozyme Therapeutics: FDA OKs RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer https://www.crweworld.com/article/news-provided-by-pr-newswire/3764618/us-fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-co-formulated-with-enhanze-for-the-treatment-of-advanced-egfr-mutated-non-small-cell-lung-cancer
0 · Reply